glp 1 and glp 2 Effects of glucagon-like peptide (GLP-2; produced by endocrine L Glucagon-like peptide 1 (GLP-1) -

Since the development of the first GLP-1 medication, Byetta, by Amylin Pharmaceuticals in 2005 and its commercialization by AstraZeneca, these drugs have been widely used for managing type 2 diabetes

Multifocal brain damage induced by phencyclidine is augmented by pilocarpine

The effects of treatment with L-carnitine of hypoglycemia in preterm AGA infants

& Munday, C

This compound is supplied exclusively for research use, supporting structured investigations centered on peptide characterization and experimental study protocols

Infections, Genetic and Environmental Factors in Pathogenesis of Autoimmune Thyroid Diseases